Aim To explore changes in body weight and cardiometabolic risk factors after treatment
withdrawal in the STEP 1 trial extension. Materials and Methods STEP 1 (NCT03548935) …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-
like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …

Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Importance No retrospective cohort study has assessed the effectiveness of semaglutide at
doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg). Objective To …

Purpose This meta-analysis aimed to assess the efficacy and safety of once-weekly
semaglutide among adults with overweight or obesity. Methods We searched multiple …

Obesity is a chronic, relapsing disease associated with multiple complications and a
substantial morbidity, mortality and health care burden. Pharmacological treatments for …

Abstract Losses of 5–10% or more of initial body weight are associated with improvements
in obesity-related comorbidities. However, attaining and sustaining this level of weight loss …

Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …